[2][3] By 2012, it had additional offices in Cambridge, Massachusetts, Tokyo, Taipei and Delhi, with staff largely from research backgrounds (30% having a PhD)[4] and had built a userbase of around 250,000 users in both academic institutions and biotechnology companies.

[5][6] CLC bio was acquired by QIAGEN in 2013 and merged into its bioinformatics research and development division with several other purchased platforms in 2014.

CLC bio developed some of their own open source algorithms, as well as their own SIMD-accelerated implementations of several existing popular applications.

[10] As additional capabilities were added to the software platform, it was eventually split into several themed Workbenches and plugins with collections of features relevant to different applications (e.g. pathway analysis, genomics, and other omics).

[citation needed] Early on, the company initially presented own-developed high-performance computing solutions, focusing on accelerating open source algorithms such as HMMER, Smith-Waterman and ClustalW, using FPGA technology.